Mini reviewPublished 4 Feb 2021
Organic Chemistry 2020: Novel orally-active NPFF receptor antagonists preventing opioid-induced hyperalgesia during the treatment of acute or chronic pains - University of Strasbourg
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The development of drugs that can more effectively and safely treat both acute and chronic pain remains a major unmet challenge in pharmaceutical industry. Opiate analgesics, such as morphine or fentanyl, continue to be the cornerstone medication for treating moderate to severe pain, but their use upon chronic administration suffers from important side-effects such as tolerance, addiction and hyperalgesia. Several anti-opioid systems have been reported as valuable targets for blocking opioid-induced hyperalgesia (OIH). Among them, the NPFF receptors belonging to the GPCR family were recently identified as one of the keystone of the opioid-induced hyperalgesia. We developed the first NPFF-receptor antagonist (RF9), and its co-administration with opioid analgesics (fentanyl) led to block the delayed and long lasting paradoxical opioid induced-hyperalgesia and prevent the development of associated tolerance. However, the dipeptide nature of RF9 limited its application to sc or iv administration. Based on an extensive SAR study, we developed a peptidomimetic of RF9 containing novel unnatural aminoacids. These basic amino acids were obtained through a specific Ru-catalyzed reduction of tertiary amides to afford in very high yields novel families of chiral α or β ϒ amino acids exhibiting a large diversity of basic side chains. Obtained at a gram-scale, these unnatural amino acids are directly suitable for peptide synthesis in liquid or solid phase. When applied to the development of new ligand of NPFF receptors, we were able to design and synthesize RF313 as the first orallyactive NPFF receptor antagonist able to reverse opioid-induced hyperalgesia in several pain models (post-operative pain, neuropathic pain, inflammatory pain). Active at low dose (1 mg/kg p.o. in rat), RF313 is also able to extend the duration of the analgesic effect induced by the opiates, opening the way to a promising therapeutic pathway to treat acute or chronic pain.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Drugs and Ecotoxicology
- SubjectPharmaceutical Sciences
- SubjectToxicology
- BylineArticles whose byline prints “F Bihel”
